摘要
目的观察低分子肝素治疗慢性阻塞性肺疾病急性加重期(AECOPD)的临床效果。方法 81例AECOPD患者随机分为治疗组41例和对照组40例,2组均给予吸氧、扩张支气管、祛痰、抗感染等常规治疗,治疗组在此基础上加用低分子肝素治疗,观察2组临床疗效。结果治疗组总有效率为90.2%高于对照组的65.0%,而平均住院时间(11.9±3.4)d短于对照组的(14.1±3.7)d,差异均有统计学意义(P<0.01和P<0.05),治疗组凝血功能和肺通气功能改善情况优于对照组,D-二聚体(DD)水平低于对照组,差异均有统计学意义(P<0.01)。结论低分子肝素抗凝治疗AECOPD疗效肯定,能明显改善患者血液高凝状态和临床症状,值得临床推广应用。
Objective To observe the clinical effect of lower molecular weight heparin（LMWH） in the treatment of acute exacerbation of chronic obstructive pulmonary disease（AECOPD）.Methods 81 cases were randomly divided into treatment group 41 cases and control group 40 cases.Both groups received conventional treatment including the oxygen uptake,the expansion bronchial tube,dispelling phlegm and antisepsis etc,moreover,the treatment group received LMWH injection.Observed the clinical effect.Results The total effective rate of the treatment group was 90.2% higher than 65.0% of the control group;The average hospitalization time of the treatment group was（11.9 ± 3.4） d shorter than（14.1 ± 3.7） d of the control group and the difference was significant（P 0.01） ;Compared with the control group,the treatment group＇s blood coagulation and lung ventilation function improved,and D-dimer level dropped.All the differences were statistically significant（P 0.01 and P 0.05）.Conclusion LMWH has definite effect on AECOPD,and it can effectively improve the blood hypercoagulable state and clinical symptoms.
出处
《临床合理用药杂志》
2010年第15期4-5,共2页
Chinese Journal of Clinical Rational Drug Use
关键词
低分子肝素
治疗
肺病
慢性阻塞性
急性加重期
临床观察
Lower molecular weight heparin
Treat
Lung disease
chronic obstructive pulmonary
Acute exacerbation period
Clinical observation
